Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 16,859 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Interventions: topiramate, Placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 17 more

Conditions: Covid19, Coronavirus, SARS-CoV Infection
Interventions: SARS-CoV-2; Diagnostic Test
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 232 participants
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Interventions: Monzosertib, Posaconazole, Isavuconazole; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: FOYC, Goal for it (GFI), Wonderous Wetlands, Caribbean Informed Parents and Children Together (CImPACT), Bahamian Focus on Older Youth (BFOOY), Health and Family Life Curriculum (HFLE); Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: Not listed
Enrollment: 1,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Coronary Artery Disease, Microvascular Coronary Artery Disease
Interventions: Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Coronary Flow Reserve, Microvascular resistance; Diagnostic Test
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Other
Eligibility: 18 Years and older
Enrollment: 2,322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Restless Legs Syndrome (RLS)
Interventions: Investigational Extended Duration (XD-) TOMAC Therapy, Tonic Motor Activation (TOMAC) Therapy; Device
Lead sponsor: Noctrix Health, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose, placebo; Biological · Dietary Supplement · Drug + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Heart Failure, Sleep Disordered Breathing
Interventions: Dapagliflozin, WatchPat; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 56 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more

Conditions: Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
Interventions: Alteplase 50 MG [Activase]; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more

Conditions: Neoplasm, Sepsis
Interventions: Gorbly Compression Device; Device
Lead sponsor: University of Miami; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions: Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells; Genetic · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 99 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Upper-Airway Cough Syndrome
Interventions: Laryngeal cryotherapy, Cryoprobe; Procedure · Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Irritable Bowel Syndrome, Visceral Hypersensitivity
Interventions: Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Long COVID Fatigue
Interventions: Ketogenic Metabolic Therapy, Lifestyle Intervention; Other · Behavioral
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: HIV Infections, AIDS
Interventions: stavudine, efavirenz, lamivudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • West Hollywood, California + 16 more

Conditions: Alcohol Use Disorder, Risk Behavior, Health, Dysbiosis, HIV Infections
Interventions: Screening, Brief Intervention, Referral to Treatment (SBIRT); Behavioral
Lead sponsor: Shirish S Barve; Other
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Obstructive Sleep Apnea
Interventions: Patient decision aid, General sleep education; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Respiratory Distress Syndrome (ARDS)
Interventions: Budesonide, Placebo, Formoterol; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Tucson, Arizona • Stanford, California • Jacksonville, Florida + 2 more

Conditions: Proteinuria, Kidney Injury, Chronic Kidney Disease
Interventions: Not listed
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years to 90 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinaemia, Hyperimmunoglobulin M Syndrome
Interventions: Subgam; Biological
Lead sponsor: Bio Products Laboratory; Other
Eligibility: 2 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Chandler, Arizona • Irvine, California • San Diego, California + 12 more

Conditions: HIV -1 Infection, HIV Infections
Interventions: PRO 140 (humanized monoclonal antibody to CCR5), Placebo Comparator; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Cabotegravir tablet 30 mg once daily for 28 days., Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland • Pittsburgh, Pennsylvania

Search by objective public record fields.

Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)

Serology to COVID-19 for Recording Exposures and Evaluating Needs

Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

HIV Risk Reduction in Youth in the Bahamas

Inclusive Invasive Physiological Assessment in Angina Syndromes Registry

Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS)

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

SGLT2-Inhibitors for Sleep Apnea in Heart Failure

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

Gorbly Compression Device for Use in Image-guided Procedures

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

Laryngeal Cryotherapy for Refractory Neurogenic Cough

Gut Permeability, Sensitivity and Symptomatology

Fully Remote, Telehealth-based Ketogenic Metabolic Therapy for Long COVID

A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients

Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)

Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention

Improving Older Adults' Decision Making for OSAT

LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers